Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC division's new responsibilities under FDA guidelines should be phased in -- NDMA.

This article was originally published in The Tan Sheet

Executive Summary

FDA OTC DIVISION PHASE-IN OF Rx-TO-OTC SWITCH POST-APPROVAL OVERSIGHT urged by the Nonprescription Drug Manufacturers Association in an Aug. 16 letter to Murray Lumpkin, MD, deputy director for review management at FDA's Center for Drug Evaluation & Research. Commenting on a recently released draft of FDA internal guidelines that would expand the OTC division's purview over NDAed OTCs, NDMA suggested "staged implementation of [the division's] responsibilities in the post-approval oversight of OTC NDAs (e.g., starting with ODE V) in order to ensure a smooth stepwise implementation."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel